Why eXoZymes, Inc.’s (EXOZ) Stock Is Up 7.28%
As of Tuesday, September 01, eXoZymes, Inc.’s EXOZ share price has surged by 7.28%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Commentary & Analysis
Why eXoZymes, Inc.’s (EXOZ) Stock Is Up 7.13%
As of Tuesday, September 01, eXoZymes, Inc.’s EXOZ share price has surged by 7.13%, which has investors questioning if this is right time to sell.Michael Rose
Why eXoZymes, Inc.’s (EXOZ) Stock Is Down 6.11%
As of Monday, August 31, eXoZymes, Inc.’s EXOZ share price has dipped by 6.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why eXoZymes, Inc.’s (EXOZ) Stock Is Down 6.48%
As of Friday, August 28, eXoZymes, Inc.’s EXOZ share price has dipped by 6.48%, which has investors questioning if this is right time to buy.Michael Rose
Why eXoZymes, Inc.’s (EXOZ) Stock Is Down 9.01%
As of Wednesday, August 26, eXoZymes, Inc.’s EXOZ share price has dipped by 9.01%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | EXOZ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $63.0 | $288.9 | 17% |
|
| Shares Out (Mil) | 8.7 | 54.0 | 19% |
|
| Institutional Ownership | 65.4% | 93.1% | 41% |
|
| Float (Mil) | 7.1 | 41.4 | 15% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 4 | 480 | 13% |
|
| Price Change (52-week) |
(31.0%) | 59.9% | 23% |
|
| Growth | EXOZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EXOZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($43) | 29% |
|
| EPS (TTM) | ($1.202) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($31) | 23% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $61 | $190 | 17% |
|
| Valuation | EXOZ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.41 | 2.84 | 95% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EXOZ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (115.4%) | (47.7%) | 5% |
|
| ROE | (187.2%) | (55.0%) | 5% |
|
| Liabilities to Assets | 54.2% | 29.6% | 47% |
|
| F-Score | 2 | 3 | 7% |
|
eXoZymes, Inc. did not pass any screens on 9/2/2026.
